FDA
-
-
-
-
-
-
-
NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19
-
-
-
-
-
-
-
NeuroRx, Relief, and Quantum Leap announce the inclusion of ZYESAMI™ (RLF-100™: aviptadil) in the I-SPY COVID-19 Trial
-
328,608 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

